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ABSTRACT
Background: Sporotrichosis is a zoonosis caused by fungi of the Sporothrix schenckii complex. Cats have important 
zoonotic potential due to the high parasite load found in the cutaneous lesions. Refractory cases to antifungal therapy are 
increasing, becoming a public health problem. Miltefosine is a drug with high in vitro activity against Sporothrix brasilien-
sis. However, this efficacy has not been confirmed in vivo yet and administration has not been studied in the feline species. 
This study aimed to evaluate the effectiveness and safety of miltefosine administration in cats with resistant sporotrichosis.
Materials, Methods & Results: Ten cats with refractory sporotrichosis were included in this study. Inclusion criteria were 
previous diagnosis for sporotrichosis associated with therapy with oral antifungals (itraconazole and/or potassium iodide) 
for more than one year, followed by one of these conditions: incomplete clinical remission, worsening of disease during 
treatment or recurrence after conventional treatment. Cats underwent clinical and dermatological examinations. Data on 
lifestyle and previous treatments were provided by the owners. Fungal culture and histochemical techniques were performed 
in all cats before miltefosine treatment. Blood samples were collected before and during the study for laboratory tests, such 
as blood count, blood urea nitrogen (BUN), serum creatinine, alanine aminotransferase (ALT) and alkaline phosphatase, as 
well as serology for Feline Immunodeficiency (FIV) and Feline Leukemia (FeLV). Miltefosine was prescribed at a dosage 
of 2 mg/kg orally every 24 h. The animals were monitored by phone during the whole process and reassessed on days 0, 
15, 30 and 45 of the treatment. Out of 10 cats, lesions were present on the nose in nine, ears in four, periocular areas in 
one and limbs in four. One cat received treatment for 45 days, six for 30 days, one for 21 days, one for 15 days and one 
for 3 days. One cat showed no response to the treatment and nine showed disease progression. Hyporexia and weight 
loss were the most frequent clinical signs related to miltefosine treatment, followed by sialorrhea, vomiting and diarrhea. 
Few adverse effects on hematology and biochemistry (mainly renal and hepatic parameters) were observed during the 
study. Hematocrit decrease was observed in four animals. However, only one cat had hematocrit decrease below normal 
values (anemia), which was already present before miltefosine administration. Other cats had a decrease of five points. 
Three cats showed elevation in leucometria and four in plasma protein. In relation to renal and hepatic biochemistry, one 
animal showed a BUN increase and another one showed a transient increase in ALT. Two animals started the treatment 
with increased ALT but had no problems during the study and values decreased even during the miltefosine administration.
Discussion: Although two cats showed sialorrhea, most owners did not report difficulty in administering the drug orally, 
representing an advantage of this medication. Weight loss, secondary to gastrointestinal changes, was the most clinically 
relevant alteration. The most frequent hematological alteration was hematocrit decrease and only the animal that started 
the study with 20% hematocrit ended the study with anemia. Renal and hepatic parameters were not significant in the 
cats of this study. Miltefosine did not lead to sporotrichosis remission in this small population of cats, which reveals that, 
despite its in vitro efficacy against Sporothrix spp., the drug is not effective in vivo in the feline species. Further studies are 
needed to investigate the efficacy of this drug in a larger number of cats, and possible reasons for its in vivo ineffectiveness.
Keywords: zoonosis, sporotrichosis, resistance, refractory, treatment, miltefosine. 
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INTRODUCTION
Sporotrichosis is a zoonosis caused by spe-
cies of the pathogenic clade of the genus Sporothrix 
[6]. The infection usually results from the traumatic 
or accidental inoculation of the fungus into the skin 
through thorns or plant material. The cat has important 
zoonotic potential due to the high parasite load found 
in the cutaneous lesions, which differentiates it from 
other species [8]. 
Several species of S. schenckii were isolated 
from feline and human lesions in Brazil, and Sporothrix 
brasiliensis is considered the most prevalent species in 
this current hyperendemics [8,13,17].
Different therapeutic regimens have already 
been used in affected cats [9,10,15,16,22]. However, 
refractory cases to antifungal therapy are increasing, 
becoming a public health problem. Several factors 
may be contributing to the low percentage of cure of 
feline Sporotrichosis, such as the need for regular ad-
ministration of medications, difficulty in administering 
oral medications to cats, and increased virulence of 
Sporothrix brasiliensis [1,3]. 
Miltefosine demonstrated antiparasitic activ-
ity against Leishmania spp., Histoplasma spp. and 
Sporothrix spp. The drug has high in vitro activity 
against Sporothrix brasiliensis, because it causes loss 
of plasma membrane integrity and effects an increased 
concentration in the melanin within fungal cells 
[4,5,7,21]. However, this efficacy has not yet been 
confirmed in vivo and administration has not been 
studied in the feline species.
This study aimed to evaluate the effectiveness 
and safety of administration of miltefosine in cats with 
resistant sporotrichosis.
MATERIALS AND METHODS
Animals
The feline owners were notified about the ob-
jectives of this research and invited to sign a free and 
informed consent form. Ten cats (Felis catus), from 
2 to 9 years of age, of both genders were included in 
this study. Cats underwent clinical and dermatologi-
cal examinations, and data on life style and previous 
treatments was provided by owners. The animals were 
allocated into groups according to the distribution of 
the lesions: L1 (cutaneous lesion in only one site), L2 
(cutaneous lesions in two nonadjacent sites) and L3 
(cutaneous lesions in 3 or more nonadjacent sites) [19]. 
Extra-cutaneous clinical signs, cutaneous lesions and 
lesion site were evaluated. Treatment efficacy criteria 
were remission of extracutaneous clinical signs and 
complete healing of the skin and mucosal lesions.
 Inclusion criteria were previous fungal cul-
ture or histochemical diagnosis for sporotrichosis. All 
animals were previously treated with oral antifungals 
(itraconazole and / or potassium iodide) for more than 
one year without complete clinical remission, wors-
ening of disease during treatment or recurrence after 
conventional treatment.  
Sample collection and laboratory examination
Fungal culture and histochemical techniques 
such as Grocott’s silver stain were performed in all 
cats before miltefosine treatment. Samples for fungal 
culture were collected using a sterile swab in ulcer-
ated lesions and in cases where ulceration was not 
present (nodular lesions) a fine needle aspiration was 
performed. Isolation of Sporothrix spp. was performed 
in Sabouraud dextrose and Micosel agar medium at 
25ºC and after growth of the fungus in the filamentous 
form, samples were seeded in BHI medium at 37ºC 
for the proof of dimorphism and obtaining the yeast 
form. For the histopathological examination, punch 
skin biopsy technique was used to obtain an 8mm 
diameter fragment of ulcerated or nodular lesion. 
Anesthetic protocol was 2-4 mg / kg of meperidine 
(Dolantina®)1 intramuscularly, and 4 mg/kg of propofol 
(Propovan®)2 intravenously. The fragments were fixed 
in 10% formaldehyde, processed by routine histo-
pathological methods and sections of 5 μ were stained 
by the Grocott silver impregnation technique (GMS). 
The histopathological diagnosis was made observing 
the morphological characteristics of the fungus; pres-
ence of yeasts measuring 2 to 8 μm, in oval, round and 
elongated forms; and histochemical staining aspects. 
The sections were analyzed under a microscope (400x 
and 1000x).
Blood samples were collected for laboratory 
tests, such as blood count, BUN, serum creatinine, ALT 
and alkaline phosphatase before and during the study, 
as well as serology for Feline Immunodeficiency (FIV) 
and Feline Leukemia (FeLV) viruses.
Miltefosin administration
Miltefosine (Milteforan®)3, a drug available in 
Brazil and some european countries, was supplied to 
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owners, who were responsible for administering the 
medication at home along with food. The prescribed 
dosage was 2 mg/kg orally every 24 h. In the case of 
hyporexia and / or vomiting, ondansetron (Vonau®)4 
was given at a dose of 0.5 mg/kg orally every 12 h, 
and omeprazol (Gaviz®)5 at the dosage of 1 mg/kg, 
orally, every 24 h for the remainder of the treatment 
with miltefosine. In case of anorexia and / or marked 
weight loss, the medication was discontinued. Cats 
that did not improve after 45 days of treatment or 
had a marked disease worsening at any time were 
excluded from the study. The cats were monitored 
during the whole process and reassessed on days 
0, 15, 30 and 45 days of the treatment, by means of 
clinical and hematological examinations. Safety was 
assessed through observation of clinical and labora-
tory changes based on normal laboratory reference 
intervals.
RESULTS
Ten cats with sporotrichosis skin lesions were 
included in the study, all previously treated for more 
than one year with itraconazole at a dosage of 100 
mg/kg/day and recognized as refractory to treatment. 
Good general condition was observed in nine animals 
and only one animal exhibited the disseminated cu-
taneous form, associated with lethargy, dehydration 
and lymphadenitis. Only one cat had positive viral 
serology (FIV), although there were no clinical or 
laboratory differences from the viral serology nega-
tive cats. The most frequent extra-cutaneous signs 
were sneezing and nasal discharge (5/10), followed 
by conjunctivitis (3/10) and dyspnea (2/10). In the 
assessment of lesions distribution, four cats were clas-
sified as L1, four as L2 and two as L3. The sites with 
the highest incidence of lesions were the nose (9/10), 
ears (4/10), limbs (4/10) and periocular area (1/10) 
[Table 1]. Ulcers and nodules were the predominant 
cutaneous lesions, which were mostly located on the 
nose (9/10). Of these nine cats, six exhibited ulcers, 
three had nodules and one had both an ulcer and a 
nodule. Other lesions observed were papules, tumors, 
erythema, crust, excoriation and scars.
All ten cats included in the study had clinical 
suspicion of sporotrichosis and were being treated with 
itraconazole and / or potassium iodide for more than 
one year. Of these ten animals, six animals showed 
positive fungal culture for Sporothrix spp. In four 
cases in which fungal culture was not conclusive, the 
histopathological diagnosis using histochemical tech-
nique as the impregnation by Grocott silver was used 
to identify the fungus agent and its morphological and 
dyeing characteristics.
Treatment duration was 3 to 45 days. One 
(1/10) cat received miltefosine for 45 days, six (6/10) 
for 30 days, one (1/10) for 21 days and one (1/10) for 
15 days. Only one (1/10) cat treatment discontinued 
on the third day, due to its poor clinical condition. The 
cats in the study showed no improvement in cutaneous 
and general clinical parameters during treatment with 
miltefosine at a dosage of 2 mg/kg orally every 24 h. 
One cat showed no response to treatment and seven 
cats showed disease progression.
Miltefosine did not cause adverse/toxic events 
in the nine studied cats. Owners did not report difficulty 
in administering this medication orally. Hyporexia 
and weight loss were the most frequent clinical signs 
related to treatment (7/10), followed by sialorrhea 
(2/10), vomiting (2/10) and diarrhea (1/10). Sialorrhea 
and vomiting occurred after 3 days of treatment and 
were treated with symptomatic therapy. These adverse 
effects were transient and their control was obtained 
without interruption of treatment. Diarrhea and dehy-
dration were observed in one (1/10) animal after fifteen 
days of treatment. One (1/10) animal, which had the 
disseminated form of the disease and poor clinical 
condition presented with anorexia, apathy and disease 
progression after 3 days of treatment. One, three and 
three cats had a loss of 5%, 7% and 10-12% of body 
weight, respectively (Table 2). 
Few hematologic and biochemical (mainly 
renal and hepatic parameters) changes were found dur-
ing the assay. Hematocrit decrease was observed in 4 
(4/10) animals. However, only one cat had hematocrit 
decrease below normal values (anemia), which was al-
ready present before miltefosine administration. Other 
cats had a decrease of 5 points. Three cats presented 
with elevation in leucometria and four cats in plasma 
protein. In relation to renal and hepatic biochemistry, 
only one animal showed a BUN increase and one ani-
mal showed a transient increase in ALT. Two animals 
had started treatment with increased ALT but had no 
problems during the study and values decreased even 
during miltefosine administration. The hematological 
and biochemical results found in the study are sum-
marized in Table 3.
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A B
Figure 1. Cat with refractory sporotrichosis before (A) and 45 days after (B) treatment with oral miltefosine. Note 
evident worsening of the cutaneous lesion (disease progression).
Table 1. Information on age, sex, FIV / FeLV status, distribution and location of skin lesions and laboratorial results of cats with refractory sporotrichosis 
treated with miltefosine.
Cat Age Gender FIV/FelV Lesion distribution Lesion site Culture Grocott
1 9 M Negative L2 Nasal planum/pinna Positive +
2 5 F Negative L1 Nasal planum Negative +
3 5 M Negative L2 Nasal planum/ pinna Negative +
4 M Negative L3 Nasal planum/pinna/Periocular/limb/tail Positive +
5 4 M FIV + L2 limbs Positive +
6 M Negative L1 Nasal planum Negative +
7 M Negative L3 Nasal planum/pinna/limbs Positive +
8 M Negative L2 Nasal planum/limb Negative +
9 4 F Negative L1 Nasal planum Positive +
10 2 F Negative L1 Nasal planum Positive +
FIV (Feline Immunodeficiency Virus); FeLV (Feline Leukemia Virus).
Table 2. Clinical evaluation and weight loss of cats during treatment with miltefosine.
Cat Treatment (days) Revision 1 (15 days) Revision 2 (30 days)
Revision 3  
(45 days)
1 21 Hyporexia, dehydration 7%. diarrhea and lesion 
worsening., weight loss (200 g) - -
2 15 Salivation,  hyporexia, vomiting after miltefosin 
administration, lesion with a drier appearance - -
3 45
Hyporexia, vomiting in the third miltefosin 
administration. lesion with a drier appearance, 
weight loss (200 g)
Sialorrhea, lesion 
worsening, weight 
loss (100 g)
Lesion worsening, 
weight loss (200 g)
4 3 Anorexia, lesion worsening, weight loss (500 g) - -
5 30 Lesions without obvious changes
Anorexia, lesion 
worsening, weight 
loss (500 g)
-
6 30 Lesion worsening, weight loss (100 g) Lesion worsening, 
weight loss (150 g) -
7 30 Lesion worsening, weight gain (270 g) Lesion worsening, 
weight gain (330 g) -
8 30 Lesion worsening. Lesion worsening, 
weight gain (200 g) -
9 30 Lesions without obvious changes,
 weight gain (300 g)
Lesion worsening, 
weight gain (100 g) -
10 30 Hiporexia, lesion worsening. Lesion worsening -
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Table 3. Hematological and biochemical results of cats with sporotrichosis during treatment with miltefosine.
Days 1 2 3 4 5 6 7 8 9 10
PCV
(24-45%)
0 36 43.4 43.0 37.3 43.3 37.0 20.0 30.3 38.0 41.6
15 28.9 39.9 39.2 38.6 38.7 39.7 20.2 33.8 - -
30 - - 39.0 - 47.0 - 22.6 36.6 - -
45 - - 37.7 - - - - - - -
GL
(6-19 mil/mm3)
0 13.9 20.9 11.3 11.3 15.8 10.9 41.1 8.1 11.7 15.1
15 26.3 8.7 8.8 23.8 17.1 17.8 39.0 11.0 - -
30 - - 8.3 - 26.1 - 36.8 11.7 - -
45 - - 8.2 - - - - - - -
Platelets
(150-800 mil/μL)
0 271 318 418 533 575 271 326 261 382 202
15 125 365 216 246 205 363 542 314 - -
30 - - 479 - 451 - 506 332 - -
45 - - 439 - - - - - - -
Plasmatic protein
(3.00-8.00)
0 9.8 9.0 8.6 7.6 9.4 7.0 8.8 7.2 7.4 7.6
15 8.2 8.4 7.8 9.2 8.8 8.2 9.2 9.0 - -
30 - - 7.4 - 9.4 - 9.2 8.8 - -
45 - - 7.0 - - - - - - -
BUN
(22 - 64)
0 29.9 48.0 63.0 34.0 33.0 62.0 55.0 49.0 47.0 72.0
15 31.0 37.0 59.0 31.0 43.0 79.0 27.0 18.0 - -
30 - - 59.0 - 33.0 - 45.0 29.0 - -
45 - - 21.0 - - - - - - -
Creatinine
(0.8 a 1.80)
0 1.0 1.5 1.5 0.8 1.0 1.7 1.6 1.0 1.1 0.5
15 0.5 0.8 1.4 0.7 1.4 1.6 1.1 0.8 - -
30 - - 1.4 - 1.2 - 1.6 0.8 - -
45 - - 1.1 - - - - - - -
ALT
(10-80)
0 90.3 27.0 42.0 20.0 33.0 33.0 69.0 38.0 27.0 87.0
15 41.0 19.0 47.0 64.0 38.2 45.0 82.0 38.0 - -
30 - - 24.0 - 13.0 - 52.0 62.0 - -
45 - - 15.0 - - - - - - -
ALP
(15-80)
0 52.6 18.0 15.0 22.0 15.0 16.0 55.0 15.0 24.0 13.0
15 - 24.0 15.0 16.0 31.0 27.0 20.0 20.0 - -
30 - - 19.0 - 19.0 - 41.0 41.0 - -
45 - - 17.0 - - - - - - -
PCV (Packed Cell Volume); GL (Global leucometry); ALT (Alanine aminotransferase); ALP (Alkaline Phosphatase).
DISCUSSION
To the authors’ knowledge, this is the first time that 
miltefosine was administered to cats with refractory spo-
rotrichosis for evaluation of its effectiveness and safety. In 
the present study, miltefosine did not lead to sporotrichosis 
remission in this small population of cats, which reveals 
that, despite its in vitro efficacy against Sporothrix spp., 
the drug is not effective in vivo in the feline species. The 
reasons for clinical failure are undetermined at this time.
Most of observed skin lesions were nodules 
and ulcers in the nasal planum. All the negative cases 
in the fungal culture were of samples collected in the 
nasal planum, (3/4) in nodules and (1/4) in ulcer. It was 
observed an inverse correlation between the presence 
of granulomas and the number of fungal structures of 
S. schenckii in the inflammatory infiltrate of cats [19]. 
Although fungal culture is the gold standard technique 
for the diagnosis of sporotrichosis [18], fungal organ-
isms in cats are considered highly characteristic in the 
tissues and histopathology is a viable and quicker op-
tion for the diagnosis of this mycosis in cats, especially 
when fungal isolation is not possible [14,20]. 
The adverse effects to miltefosine observed in 
this study were hyporexia (7/10), sialorrhea (2/10), vom-
iting (2/10) and diarrhea (1/10). Weight loss, secondary 
to gastrointestinal changes, was the most clinically rel-
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evant alteration and was present in nine (9/10) animals 
of the study, of which, one cat had 5% loss of body 
weight, three cats had 7%, and three cats had 10-12% 
loss of body weight. In studies on the safety of the use 
of Miltefosine in dogs as a single therapy or associated 
with allopurinol, transient self-limiting and revers-
ible episodes of vomiting were the main side effects 
[2,11,12,23]. Although two cats showed sialorrhea, most 
owners did not report difficulty in administering the drug 
orally, representing an advantage of this medication.
The most frequent hematological alteration was 
hematocrit decrease, which occurred in four (4/10) animals 
and only the animal that started the study with 20% hema-
tocrit ended the study presenting anemia. In patients with 
visceral leishmaniasis (VL), rapid recovery from anemia, 
leukopenia and thrombocytopenia were observed [21].
Renal and hepatic parameters were not sig-
nificant in cats of this study. Only one animal had a 
slight BUN increase and one animal showed a transient 
increase in ALT. One animal that started treatment with 
elevated ALT followed with decreasing of these values 
throughout the study. These data corroborate with 
several studies on the safety of the use of miltefosine 
in dogs, which observed low effect on hematology and 
renal and hepatic functions [11,23].
CONCLUSION
Miltefosine did not lead to clinical remission 
of refractory sporotrichosis to conventional treatment 
with itraconazole and / or potassium iodide in this small 
cohort of cats. Further studies are needed to investigate 
the efficacy of this drug in feline species in a larger 
number of animals, and possible reasons for its in vivo 
ineffectiveness in feline species.
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